Chemotherapeutic Induction of Single-Stranded DNA Accumulation Sensitizes Triple-Negative Breast Cancer to Immunotherapy [scRNA-seq]
Single-cell RNA-seq · mouse · 32 samples
- What it is
- Single-cell RNA-seqGene activity measured in thousands of individual cells, so cell types can be told apart.
- Organism
- Mus musculus (mouse)
- Samples
- 32 samples: 9 × 4T1 IgG+Vehicle vs 8 × 4T1 Anti-PD1+Vehicle vs 8 × 4T1 Anti-PD1+LP-184 vs 7 × 4T1 IgG+LP-184Groups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE311488_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Single-cell studies usually ship their counts as 10x files (matrix.mtx, barcodes.tsv, features.tsv), an .h5 file, or an .rds / .h5ad object that Seurat or Scanpy can open. Look for those among the supplementary files.
Also filed as BioProject PRJNA1369543 and SRA study SRP648972. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 32 samples.
How we read this: 4 replicated groups read from 32 sample titles; they account for 32 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9325938 4T1 IgG+Vehicle-1 4T1 IgG+Vehicle
- GSM9325939 4T1 IgG+Vehicle-2 4T1 IgG+Vehicle
- GSM9325940 4T1 IgG+Vehicle-3 4T1 IgG+Vehicle
- GSM9325941 4T1 IgG+Vehicle-4 4T1 IgG+Vehicle
- GSM9325942 4T1 IgG+Vehicle-5 4T1 IgG+Vehicle
- GSM9325943 4T1 IgG+Vehicle-6 4T1 IgG+Vehicle
- GSM9325944 4T1 IgG+Vehicle-7 4T1 IgG+Vehicle
- GSM9325945 4T1 IgG+Vehicle-8 4T1 IgG+Vehicle
- GSM9325946 4T1 IgG+Vehicle-9 4T1 IgG+Vehicle
- GSM9325947 4T1 IgG+LP-184-1 4T1 IgG+LP-184
- GSM9325948 4T1 IgG+LP-184-2 4T1 IgG+LP-184
- GSM9325949 4T1 IgG+LP-184-3 4T1 IgG+LP-184
- GSM9325950 4T1 IgG+LP-184-4 4T1 IgG+LP-184
- GSM9325951 4T1 IgG+LP-184-5 4T1 IgG+LP-184
- GSM9325952 4T1 IgG+LP-184-6 4T1 IgG+LP-184
- GSM9325953 4T1 IgG+LP-184-7 4T1 IgG+LP-184
- GSM9325954 4T1 Anti-PD1+Vehicle-1 4T1 Anti-PD1+Vehicle
- GSM9325955 4T1 Anti-PD1+Vehicle-2 4T1 Anti-PD1+Vehicle
- GSM9325956 4T1 Anti-PD1+Vehicle-3 4T1 Anti-PD1+Vehicle
- GSM9325957 4T1 Anti-PD1+Vehicle-4 4T1 Anti-PD1+Vehicle
- GSM9325958 4T1 Anti-PD1+Vehicle-5 4T1 Anti-PD1+Vehicle
- GSM9325959 4T1 Anti-PD1+Vehicle-6 4T1 Anti-PD1+Vehicle
- GSM9325960 4T1 Anti-PD1+Vehicle-7 4T1 Anti-PD1+Vehicle
- GSM9325961 4T1 Anti-PD1+Vehicle-8 4T1 Anti-PD1+Vehicle
- GSM9325962 4T1 Anti-PD1+LP-184-1 4T1 Anti-PD1+LP-184
- GSM9325963 4T1 Anti-PD1+LP-184-2 4T1 Anti-PD1+LP-184
- GSM9325964 4T1 Anti-PD1+LP-184-3 4T1 Anti-PD1+LP-184
- GSM9325965 4T1 Anti-PD1+LP-184-4 4T1 Anti-PD1+LP-184
- GSM9325966 4T1 Anti-PD1+LP-184-5 4T1 Anti-PD1+LP-184
- GSM9325967 4T1 Anti-PD1+LP-184-6 4T1 Anti-PD1+LP-184
- GSM9325968 4T1 Anti-PD1+LP-184-7 4T1 Anti-PD1+LP-184
- GSM9325969 4T1 Anti-PD1+LP-184-8 4T1 Anti-PD1+LP-184
- GSE215960 Subclonal evolution revealed by single-cell profiles of expressed mutations identifies adaptation mechanisms to immunotherapy in melanoma [scRNA-seq] 192 samples shares immunotherapy, scrna-seq
- GSE302715 A tumor-associated macrophage-targeted immunocytokine leveraging T and NK cell synergy for potent cancer immunotherapy [scRNA-seq] 187 samples shares immunotherapy, scrna-seq
- GSE294999 Obesity-driven inflammation enables triple-negative breast cancer progression through immunosuppression [scRNA-Seq] 16 samples shares triple-negative, scrna-seq
- GSE297817 Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy [DASAITC] 15 samples shares immunotherapy, sensitizes
- GSE289275 Loss of ADAR1 in tumor cells activates cDC1s and sensitizes pancreatic cancer to immunotherapy 14 samples shares immunotherapy, sensitizes
- GSE249759 In vivo CRISPR screens identify Mga as an immunotherapy target in triple-negative breast cancer 12 samples shares triple-negative, immunotherapy
- GSE249630 Modeling T cell temporal response to cancer immunotherapy rationalize development of combinatorial treatments protocols 1372 samples shares immunotherapy
- GSE342349 CT26 multi-tissue RNA-seq under immunotherapy combinations 72 samples shares immunotherapy
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.